{"title":"Pregnancy outcomes following first trimester exposure to semaglutide.","authors":"Adam Morton, Jinwen He","doi":"10.1177/1753495X251346330","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>To review pregnancy outcomes in women exposed to semaglutide during early pregnancy.</p><p><strong>Methods: </strong>A retrospective review of an obstetric database at a tertiary obstetric hospital in Brisbane, Australia.</p><p><strong>Results: </strong>Thirteen women were exposed to semaglutide in first trimester. One infant had significant cardiac anomalies in the setting of very poor maternal glycaemic control in first trimester, as well as maternal obesity and hypertension.</p><p><strong>Conclusion: </strong>This study adds to the growing literature suggesting there is no increased risk of major congenital anomalies following first trimester exposure to semaglutide, however, until larger studies are available to confirm these findings, reproductive-age women using semaglutide should practice effective contraceptive methods. Preconception counselling of all women with diabetes mellitus is critical to avoid adverse pregnancy outcomes.</p>","PeriodicalId":51717,"journal":{"name":"Obstetric Medicine","volume":" ","pages":"1753495X251346330"},"PeriodicalIF":0.8000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141256/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetric Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/1753495X251346330","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and objective: To review pregnancy outcomes in women exposed to semaglutide during early pregnancy.
Methods: A retrospective review of an obstetric database at a tertiary obstetric hospital in Brisbane, Australia.
Results: Thirteen women were exposed to semaglutide in first trimester. One infant had significant cardiac anomalies in the setting of very poor maternal glycaemic control in first trimester, as well as maternal obesity and hypertension.
Conclusion: This study adds to the growing literature suggesting there is no increased risk of major congenital anomalies following first trimester exposure to semaglutide, however, until larger studies are available to confirm these findings, reproductive-age women using semaglutide should practice effective contraceptive methods. Preconception counselling of all women with diabetes mellitus is critical to avoid adverse pregnancy outcomes.